- Home
- Equipment
- usa washington
- therapy evading cancers
Refine by
Therapy Evading Cancers Equipment Supplied In Usa Washington
4 equipment items found
by:Zymeworks Inc based inVancouver, BRITISH COLUMBIA (CANADA)
Zymeworks’ lead product candidate, zanidatamab, is a HER2-targeted bispecific antibody developed using Zymeworks proprietary Azymetric platform. Zanidatamab is currently being evaluated in global Phase 1, Phase 2 and pivotal clinical trials as a best-in-class treatment for patients with HER2-expressing cancers, including biliary tract, gastroesophageal adenocarcinomas, breast, and other ...
Manufactured by:Adaptive Biotechnologies based inSeattle, WASHINGTON (USA)
We are currently leveraging our TCR discovery capabilities to enable commercialization of novel therapies by collaborators. In the future, we may explore expanding our end-to-end capabilities for the development of cellular therapies and vaccines. TruTCR is summarized in the figure ...
Manufactured by:SEngine Precision Medicine based inSeattle, WASHINGTON (USA)
Guiding drug discovery with proprietary high throughput 3D patient cell technology and genomics will drastically increase the success of novel drug candidates and directly result in faster development at reduced costs. SEngine Precision Medicine’s innovative approach brings diagnostics, drug discovery and proprietary algorithms together with our patient-derived 3D tumor organoids to ...
Manufactured by:Aptevo Therapeutics based inSeattle, WASHINGTON (USA)
ALG.APV-527 is a bispecific antibody candidate targeting 4-1BB x 5T4 and is intended for tumor-directed treatment of solid cancers. It was built using Aptevo’s ADAPTIR™ bispecific technology platform and combines binding domains sourced from Alligator Biosciences’ ALLIGATOR-GOLD® human scFv ...